Novartis Venture Fund - aVenture Asset Manager Research
Location
Basel, Basel-Stadt, CH
Founded
1996
Novartis Venture Fund is a venture capital firm specializing in the development and investment of innovative therapeutics. The firm focuses on biotechnology and biopharmaceuticals, investing in companies at all stages of growth and development. Their typical investment rounds include Series A, B, and C, with substantial investments in Series A (28 rounds) and Series B (22 rounds). They manage significant committed capital to foster innovation and drive patient benefits globally.
Notable portfolio companies include Acorda Therapeutics, Akebia Therapeutics, Bionano Genomics, and GentiBio. The fund is led by key partners with extensive experience in life sciences and venture capital. Novartis Venture Fund emphasizes unmet medical needs, proprietary science, and capital efficiency. They offer unique value-add services such as strategic guidance, industry connections, and operational support to help portfolio companies achieve clinical and commercial success.
Novartis Venture Fund - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
